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ABSTRACT: The development of resistance to targeted therapeu-
tics is a challenging issue for the treatment of cancer. Cancers that
have mutations in BRCA, a DNA repair protein, have been treated
with poly(ADP-ribose) polymerase (PARP) inhibitors, which target
a second DNA repair mechanism with the aim of inducing
synthetic lethality. While these inhibitors have shown promise
clinically, the development of resistance can limit their effective-
ness as a therapy. This study investigated mechanisms of
resistance in BRCA-mutated cancer cells (HCC1937) to Olaparib
(AZD2281) using TRACER, a technique for measuring dynamics of
transcription factor (TF) activity in living cells. TF activity was
monitored in the parental HCC1937 cell line and two distinct
resistant cell lines, one with restored wild-type BRCA1 and one
with acquired resistance independent of BRCA1 for 48 h during
treatment with Olaparib. Partial least squares discriminant
analysis (PLSDA) was used to categorize the three cell types
based on TF activity, and network analysis was used to investigate
the mechanism of early response to Olaparib in the study cells.
NOTCH signaling was identified as a common pathway linked to
resistance in both Olaparib-resistant cell types. Western blotting
confirmed upregulation of NOTCH protein, and sensitivity to
Olaparib was restored through co-treatment with a gamma
secretase inhibitor. The identification of NOTCH signaling as a
common pathway contributing to PARP inhibitor resistance by
TRACER indicates the efficacy of transcription factor dynamics in
identifying targets for intervention in treatment-resistant cancer
and provides a new method for determining effective strategies for
directed chemotherapy.
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Introduction
The genes BRCA1/BRCA2 play major roles in the repair of DNA
double-strand breaks (DSBs) by homologous recombination (HR).
HR repairs DSBs that occur in the late S and G2 phase of the cell
cycle and also has a key role in resolving DSBs that result from
unrepaired single-strand breaks (SSB). As such, mutations in the
BRCA genes lead to an increased risk of genetic mutation and the
subsequent development of cancer. Women carrying a mutation in
BRCA1 or BRCA2 have a lifetime risk of developing breast cancer of
up to 80%, with a risk of developing ovarian cancer of approximately
50% (Ford et al., 1994; King et al., 2003). Breast cancer and ovarian
cancer are often associated with mutations in BRCA, with many
BRCA1-driven breast cancers also being triple negative for the
estrogen, progesterone, and HER2/neu receptors (ER, PR,
HER2) (Foulkes et al., 2010; Reis-Filho and Tutt, 2008). Targeted
therapy for triple negative breast cancer (TNBC) is currently
lacking, and as such much research is directed toward
understanding and developing chemotherapeutics to target this
disease subtype.
One therapy targeted to BRCA-mutated cancers is the use of
poly(ADP-ribose) polymerase (PARP) inhibitors (Farmer et al.,
2005; Rottenberg et al., 2008; Rouleau et al., 2010). PARP is an
enzyme that plays an important role in the recognition and repair of
single-strand DNA breaks through the base excision repair (BER)
pathway. Targeting this mechanism with PARP1 inhibitors has
shown preclinical efficacy in tumors with homologous DNA repair
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defects, such as those arising in BRCA1 or BRCA2 mutation carriers
with breast cancer and ovarian cancer (Bryant et al., 2005; Farmer
et al., 2005). The mechanism by which PARP inhibition can
promote cell death in BRCA-mutated cells is thought to be through
synthetic lethality, defined as the co-occurrence of multiple genetic
events that results in organismal or cellular death (Lord et al., 2015).
The PARP inhibitor Olaparib (AZD2281) is a small-molecule that
has shown efficacy in patients with germline BRCA mutations in
clinical trials (Buege and Mahajan, 2015; Gelmon et al., 2011;
Ledermann et al., 2012; Tutt et al., 2009). Olaparib was recently
approved for use in late-stage ovarian cancers with deleterious
germline BRCA mutations as a result of its efficacy in clinical trials
(Kim et al., 2015). Despite the effectiveness of PARP inhibitors in
the treatment of BRCA-mutated cancers, some patients do not
respond, and others can develop resistance to the drug with
prolonged treatment. The mechanisms governing lack of respon-
siveness or the development of resistance are thought to occur
through alterations in the transcriptional network (Barber et al.,
2013; Henneman et al., 2015; Jaspers et al., 2013; Johnson et al.,
2013; Lord and Ashworth, 2013). Identification of these changes
offers the opportunity to develop combination therapy strategies
that can enhance the efficacy of PARP inhibitors while also
preventing the development of resistance.
The objective of this study was to quantify the regulatory
dynamics of breast cancer cells in response to Olaparib treatment
using cells that are both sensitive and resistant to PARP inhibition.
We applied a TRanscriptional Activity CEll aRray (TRACER) to
measure the large-scale dynamic activity of multiple transcription
factors (TFs) that occur in response to Olaparib treatment for
multiple cell populations. TRACER is distinct from other high-
throughput approaches that measure the abundance of mRNA or
protein within cells, as the repeated measurement of activity for
multiple TFs within the same cell populations enables monitoring of
the cellular adaptation to the presence of the drug and provides
information on active signaling pathways that enable resistance. We
employed data-driven modeling (Arnold et al., 2015; Beste et al.,
2014) approaches that enable evaluation of relationships between
TFs, rather than separate treatment of individual TFs. Network
analysis of TF activity provided a unique perspective for both
identifying tumor cells that are likely to be resistant to standard
therapies as well as suggesting alternative multivariate targets for
combinatorial treatment. Identifying the mechanisms of PARP1
inhibition-mediated cell death and resistance development during
treatment has the potential to identify new strategies to maximize
drug efficacy, guide associated combinatorial therapeutics to avoid
resistance, and identify biomarker signatures to identify patients
that are sensitive to PARP1 inhibitors.
Materials and Methods
Cells and Reagents
HCC1937 (BRCA1-mutated) tumor cell line is derived from a type of
human ductal carcinoma bearing a BRCA1 5382insC mutation in
one allele and a deletion of the second allele. The BRCA1 protein in
HCC1937 lacks the BRCA1C terminus, and extracts show very low
levels of BRCA1 protein. The cells were stably transfected with
either the wild-type BRCA1-expressing vector or the null vector so
that two cell lines (BRCA1 wild-type and mutant-type) were
established (kindly gifted by Dr. Vincent Cryns).
Cell Viability Assay
Cell viability was analyzed by MTS assay (Sigma, St. Louis, MO).
Cells (1500–3000) were plated in each well of a 96-well tissue
culture plate with 100mL of medium. The next day, the medium
was replaced with 100mL of fresh medium containing 10mM
Olaparib or 0.5mM gamma secretase inhibitor, as indicated, and
the cells were grown for 7 days. Stock Olaparib and gamma
secretase inhibitor were prepared in DMSO. At the end of the
treatment period, 10mL of MTS solution was added to each well,
the cells were incubated at 37C for 1–2 h, and absorbance was read
at 490 nm. Data are presented as a percentage of the control cells
cultivated under the same conditions or the absorbance of the wells.
Lentivirus
Lentivirus was produced by co-transfecting HEK-293T cells with
previously described lentiviral packaging vectors (pMDL-GagPol,
pRSV-Rev, pIVS-VSV-G) (Dull et al., 1998) and lentiviral vectors
using JetPrime (Polyplus, Illkirch, France). After 48 h, supernatants
were collected and cell debris was spun down and removed. Viruses
were concentrated using PEG-it (Systems Biosciences, Palo Alto,
CA) and re-suspended in phosphate buffered saline (PBS).
Establishment of Olaparib-Resistant Cell Line From
BRCA1 Mutant Cells
Olaparib-resistant clones were established by means of long-term
exposure to gradually increasing concentrations of Olaparib (0.2,
0.5, 1, 2, 5, 10mM, 1 week in each treatment). The cells that
survived in the final 10mM concentration of Olaparib were serially
diluted to single cells and enriched without Olaparib. After
establishing the clones, the drug resistance was confirmed and
clones were selected that had drug resistance similar to BRCA1
wild-type cells.
Reverse Transcription-PCR (RT-PCR)
RNAwas prepared from 5 105 cells by use of the Absolutely RNA
Microprep Kit (Stratagene, Santa Clara, CA). Before reverse
transcription, 1mg of RNA was treated with RNase free-DNase I.
Purified RNA (0.5mg) was reverse transcribed with random
hexamers using the Superscript III first-strand synthesis system
(Life Technologies, Carlsbad, CA). b-actin was used as an internal
control. The cycling conditions were as follows: pre-treatment at
95C for 15 s, then 40 cycles of denaturation at 95C for 5 s, and
extension at 60C for 30 s. Relative gene expression was quantified
using the comparative DCT (CT: cycle threshold) method.
Transcription Factor Activity Arrays
TF reporters consist of a specific TF response element (TRE) cloned
upstream of a minimal thymidine kinase promoter driving the gene
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for firefly luciferase (FLUC). Increased binding of TFs at the TRE
results in increased luciferase production and a proportional
increase in luminescence when an excess of substrate is added
during imaging, thus providing a quantitative measure of relative
transactivation. TF reporter specificity and sensitivity studies are
referenced on the TRANSFAC database. Each lentiviral reporter
consists of three or four repeats of a TF-specific binding element
driving expression of firefly luciferase.
Dynamic TF activity was measured for three different
populations of HCC1937 cells: parent HCC1937 cells with mutated
BRCA1 (BRCA1MT), HCC1937 cells with wild-type BRCA1
(BRCA1WT), and HCC1937 cells with mutated BRCA1 that have
been selected for resistance to Olaparib (BRCA1MT/RES). Cells with
mutated BRCA1 have impaired DNA repair and are thus sensitive to
PARP inhibitors such as Olaparib. Activity was measured for 44
different factors over 2 days of treatment with 10mM Olaparib.
Measurements acquired at several time points (0, 2, 4, 6, 8, 24, 48 h)
allowed both initial differences between cell types as well as
differences in response to Olaparib treatment to be elucidated from
the data.
All cell types were transduced with 10 MOI of each TF activity-
reporting lentivirus. Transduced cells were then seeded on a
384-well plate with at least four replicates of each condition. Two
days after cell seeding, luciferase activity was measured using an
IVIS Lumina LTE camera system (Caliper Life Sciences,
Hopkinton, MA). The 2-day period is sufficient time for ensuring
lentiviral gene expression. After changing media, cells were
treated with 10mM of Olaparib, and the luciferase activity was
measured for 2 days. TA lentivirus, which is composed of only
minimal promoter of thymidine kinase, was used as a control.
The luciferase activity from TA lentivirus transduced cells highly
correlates to cell number over time. Thus, all other TF activity
was normalized with respect to TA activity and represented by
TF/TA ratio.
Western Blot Analysis
Total cell protein was extracted in boiling SDS sample buffer
(2% SDS, 50 mmol/L Tris–HCl [pH 6.8], 10% glycerol,
0.002% bromophenol blue, and 6% 2-mercaptoethanol). Cell
extracts were separated by SDS–PAGE, and the proteins were
transferred to polyvinylidene difluoride membrane (Millipore,
Billerica, MA). Western blots were blocked in TBS-T buffer
(10 mmol/L Tris–HCl [pH 7.4], 150 mmol/L NaCl, and 0.05% [v/
v] Tween 20) containing 5% nonfat dry milk and probed with
primary antibody in blocking buffer at 4C overnight. Blots were
washed with TBS-T buffer and incubated with secondary
antibodies diluted in TBS-T at room temperature. Primary
antibodies of anti-NOTCH1 and anti-NOTCH3 were obtained
from Santa Cruz Biotechnology (Dallas, TX).
PLSDA Analysis
Partial least squares discriminant analysis (PLSDA) was
performed in order to identify patterns in TF activity that
distinguish between cell types and treatments (Benedict and
Lauffenburger, 2012). PLSDA reduces model dimensionality by
calculating orthogonal latent variables (LV) that best differentiate
between classes. Scores calculated for observations can be
plotted on LVs to allow for visualization of classification in a
scores plot. Associated latent variable loadings enable identifi-
cation of TF activity patterns associated with classification. Two
separate PLSDA models were generated in this study; one using
only data from the initial time point (single time point) and one
using measurements from multiple time points (combined time-
course). PLSDA calculations were performed using the orthogo-
nal PLSDA algorithm in PLS Toolbox (Eigenvector Research,
Manson, WA). Cross-validation was performed using k-fold
cross-validation with k¼ 10, dividing the dataset into 10 subsets
and testing each subset individually with the remaining used for
training. In addition to cross-validation, the model was further
validated by a permutation test, in which the classification
efficacy of the PLSDA model was compared to additional PLSDA
models generated using randomly permuted class labels using a
Student’s t-test. This test allowed for confirmation that the
classification between the assigned cell types was significantly
more effective than classification between random groups
(Westerhuis et al., 2008). A single time point model was created
with all cell groups (BRCA1MT, BRCA1WT, and BRCA1MT/RES) at
the initial measurement time point (48 h after seeding and
transfection). A combined time-course model was also created
using all three cell groups at multiple time points after treatment
with Olaparib. Variable importance in projection (VIP) scores
were used to select variables that were most effective in
separating classes, eliminating those that were either not helpful
or were confounding. The VIP scores for the selected variables
indicate the relative importance of each variable in modelling
the variance seen in TF activity measurements, and accordingly
the most important variable for explaining the variance
(Chong and Jun, 2005). The 35 variables with the highest VIP
scores were selected in order to keep dimensionality consistent
between single time-point and combined time-course PLSDA
models.
Statistical and Systems Analysis
TF activity levels were normalized to a TA reporter with the
corresponding treatment. We performed background subtraction
and loss normalization to correct for systematic noise. All
normalized TF activity levels were log2 transformed. Results of
experiments are presented as the mean standard deviation unless
otherwise indicated. Differences in means were evaluated by fitting
an empirical hierarchical Bayesian linear model using the limma R
package (Smyth, 2005). P-values were adjusted using the false
discovery rate correction (Benjamini and Hochberg, 1995). A
P-value of<0.05 was considered to be statistically significant. Each
individual 384-well plate included only a subset of the measured
TFs, requiring the formation of simulated multivariate observations
(containing every TF) for hierarchical clustering and PLSDA, which
were generated by randomly sampling independent TF activity
measurements from within each cell type. A total of 1000 simulated
observations were generated for each cell type in order to form a
stable distribution, without calculating all possible combinations
(>1048). Variables with more than 25% of activity measurements
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below background were removed from analysis. Mean-centering
and variance scaling were used to standardize all data prior to
multivariate analysis.
Hierarchical clustering was used to identify differences in TF
activity between cell groups in an unsupervised manner (Arnold
et al., 2016). Clustering was performed using Matlab software
(Mathworks, Natick, MA) with Pearson’s correlation coefficient as a
distance metric. The clustering results were visualized using the
clustergram function to generate a heatmap of relative TF activity
with dendrograms indicating clusters for both TFs and samples.
Network Analysis
Network analysis of TF activity measurements was carried out
using NTRACER, as described previously (Bernabe et al., 2016;
Weiss et al., 2014). Briefly, normalized activity measurements are
mean-centered and an initial network topology inferred through
several different techniques: linear methods (PLSR; [Mevik and
Wehrens, 2007], similarity index [Siletz et al., 2013], linear
ordinary differential equations based on TIGRESS [Haury et al.,
2012]), and nonlinear methods (ARACNE [Margolin et al., 2006],
CLR [Faith et al., 2007], MRNET [Meyer et al., 2007], dynamic
random forest [Breiman, 2001]). A prior knowledge network
curated from GENEGO, TRANSFAC, and IPA was also included in
the model. CellNOptR (Terfve et al., 2012) was used to optimize
the network architecture. A total of 500 runs was performed.
Edge significance was determined by comparing the number of
edge occurrences in the 500 optimized networks to 500
networks generated from permutation samples from the same
data. A P-value of 106 was used for significance. Finally,
features were selected from the top 10% of significant edges at
each set of time points to ensure high-quality edge selection.
Networks were visualized using the R package iGraph (Csardi and
Nepusz, 2006).
Results
BRCA1-Mutated HCC1937 Cancer Cells Were Sensitive to
PARP1 Inhibitor Olaparib
The sensitivity of BRCA1-mutated HCC1937 cells to the PARP1
inhibitor Olaparib (AZD2281) was initially investigated. BRCA1WT
cells were resistant to 10mM of Olaparib compared with BRCAMT
cells, with a twofold increase in cell viability after 7 days as
measured by MTS assay (Fig. 1). These data are consistent with the
previous observation that Olaparib has a cytotoxic effect on BRCA-
mutated cells.
Prolonged exposure of HCC1937 cells to increasing doses of
Olaparib over a 6-week period led to the development of resistance
at the therapeutic dose (Fig. 1). Previous reports suggested BRCA1-
mutated cell lines may develop resistance to Olaparib or other PARP
inhibitors through a secondary mutation to restore the wild-type
BRCA1 protein (Lord and Ashworth, 2013). RG-PCR for BRCA1 in
the resistant cells confirmed that the cells retained the truncated
BRCA1 mutant that is present in the parental cell line, indicating
that wild-type BRCA1 protein was not restored in these cells
(Fig. S1).
Multivariate Analysis of TF Activity Before Treatment
With Olaparib Predicted Phenotype and Provided Insight
Into Systems-Level Mechanisms
TRACER was used to profile baseline (i.e., no drug treatment)
differences in TF activity in the three cell types (Figs. 2 and S2). A
total of 68% (30/44) of examined TFs were significantly
different between BRCA1WT or BRCA1MT/RES cells and BRCAMT
(P< 0.05). Of these factors, 10 were similar between BRCA1WTand
BRCA1MT/RES, 1 was significant in BRCA1WT only, and 19 were
significant in BRCA1MT/RES only. The TFs that were common
between BRCA1WT and BRCA1MT/RES suggested that there may be
common mechanisms to producing resistance to Olaparib, while
the TFs that were distinct between the two may suggest cell-type
specific mechanisms.
Although univariate analysis may identify differences between
cell groups based on the activity measurements of individual TFs,
multivariate approaches allow for the identification of patterns in
TF activity that can improve the classification and identifying
relationships between TFs. We used hierarchical clustering to
visualize multivariate differences in differentially active TFs in an
unsupervised manner. Our results indicated distinct regulatory
activity in BRCA1MT, BRCA1WT, and BRCA1MT/RES cells (Fig. 3).
TFs associated with BRCA1MT cells include PTTG, E2F1, CRE,
and STAT3, while HOXA1, STAT5, WT, and HIF1 were associated
with BRCA1WT cells, and LHX8, IRF1, ISRE, SP1, RAR, SRF, and
OCT4 were associated with BRCA1MT/RES cells. These TFs belong
to a variety of pathways, including interferon response (IRF1 and
ISRE), development (RAR, HOXA1, and LHX8), and pluripotency
(OCT4).
PLSDA was used to identify linear combinations of TFs that
best separated the three cell lines at single time points (Fig. S3A).
PLSDA applied to TF activity data from all three cell types
(BRCA1MT, BRCA1WT, and BRCA1MT/RES) indicated separation
between groups along two latent variables, with a calibration
error ranging from 5.6% to 11.4% and a cross-validation error
Figure 1. Cell viability after 7-day treatment with 10mM Olaparib. Values are
presented as absorbance at 490 nm normalized to the parental cell line. BRCA1WT and
BRCA1MT/RES are both significantly different from BRCA1MT (P< 0.05, P< 0.01).
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from 5.7% to 11.7% (Fig. S3B). In the PLSDA model of TF activity
prior to Olaparib treatment (Time 0), the first latent variable
separated BRCA1WT and BRCA1MT cells, while the second latent
variable separated BRCA1MT/RES cells from the other types
(Fig. 4A). BRCA1MT cells were scored negatively on LV1 and LV2
and, therefore, were associated with CRE, GATA1, E2F1, and
PTTG. BRCA1WT cells, scored positively on LV1 and negatively on
LV2, were associated with HIF1, STAT5, HOXA1, and WT, and
BRCA1MT/RES cells, which scored positively on LV2, were
associated with SP1, RAR, SRF, and OCT4 (Fig. 4B). Unsurpris-
ingly, the TFs identified with each cell type using PLSDA
were similar to those identified with hierarchical clustering.
Of particular interest are TFs SRF, NOTCH, and OCT4 that
are positively loaded on both LV1 and LV2, indicating
association with both Olaparib resistant cell lines (BRCA1WT
and BRCA1MT/RES). Overall, PLSDA indicated that resistant cell
phenotype can be predicted based on relationships between
baseline TF activity measurements.
Figure 2. Dynamic transcription factor activity after treatment with Olaparib. Values are reported as log2 values for the treated condition normalized to the TA control
reporter and untreated HCC1937 cells. Colors of TF names denote significance compared to BRCAMT during at least one measurement (P< 0.05). Red, BRCAWT; Green, BRCAMT/RES;
Blue, Both.
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Measurements of Dynamic TF Activity Were More
Predictive of Resistant Cell Phenotype and Gave Insight
Into Temporal Patterns of TF Activation
Measurements from multiple time points were used to create a
combined time-course PLSDA model using data collected before
(Time 0) and after (Times 2–48) Olaparib treatment (Fig. 4C and
D). We ensured the number of parameters was matched between
combined time-course and single time point models by including
only the top 35 parameters in the combined time-course model, as
assessed by VIP scores. Interestingly, the model including temporal
information was over 10-fold more accurate for differentiating cell
phenotype (cross-validation error of 0.25%) (Fig. S3B), highlighting
the importance of the ability to measure TF activity over time.
PLSDA performed with permuted class labels performed with
significantly worse CV accuracy (P< 0.001).
Examination of latent variable loadings revealed signatures of TF
activation that may be useful in understanding differences in
temporal signaling relationships based on cell phenotype (Fig. 4D).
The first latent variable (LV) separated BRCA1WT and BRCA1MT
cells, while the second LV distinguished BRCA1MT/RES cells
(Fig. 4C). NOTCH activity measured 2 h after treatment was the
most critical component of these signatures (as assessed by VIP
score). The loadings for most TFs across time points remained
similar, suggesting similar dynamic directionality. Intriguingly,
however, NOTCH is loaded differently at each time point, indicating
that there is a change in relative activity over the course of the
experiment within different cell types. Two hours after treatment
with Olaparib, NOTCH is loaded positively on both LV1 and LV2,
associating it with the Olaparib-resistant cell types (BRCA1WT and
BRCAMT/RES). However, 48 h after treatment, NOTCH becomes
more associated with the Olaparib-sensitive BRCA1MT cell type.
NOTCH as a Common Transcription Factor in Multiple
Olaparib Resistance Mechanisms
Networks for TRACER (NTRACER) was used to identify relevant
hubs of activity leading to resistance in BRCA1WTand BRCA1MT/RES
cells (Fig. 5). These networks compared the differences in response
between sensitive and resistant cell lines in order to identify
differences in response that lead to the resistant phenotype.
Specifically, the networks at the earliest time points (0–2 h,
Fig. 5A and C) were examined to determine the initial effects of
Olaparib treatment on the inferred dynamic regulatory network.
NTRACER identified seven nodes directly connected to the
BRCA1MT/RES cell type (PTTG, RAR, SP1, SRF, STAT1, AR, and
HIF1), with five additional nodes (NOTCH, IRF1, GL1, SNAIL, and
OCT4) regulated by one or more of the cell type-associated nodes.
Similar connectivity was observed for BRCA1WT cells, with one
node (Wilms tumor [WT]) associated with the cell type and four
additional nodes (NOTCH, STAT5, HOX1A, and GL1) downstream
of the cell type-associated node. Later time points (2–4 h,
Fig. 5B and D) had increased connectivity (defined as the number
of connections for a particular node relative to the total number of
nodes in the network) of downstream nodes, particularly NOTCH,
OCT4, IRF1, and SNAIL in the BRCA1MT/RES cells and NOTCH and
GL1 in the BRCA1WT cells. The nodes are interpreted as involved in
Figure 3. Unsupervised hierarchical cluster of bootstrapped multivariate observations based on transcriptional activity at the initial time point. BRCA1MT (BRCA1 mutant,
green), BRCA1WT (BRCA1 wild-type, red), and BRCA1MT/RES cells (BRCA1 mutant with resistance to Olaparib, blue) were separated based on their transcriptional activity.
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early response to the drug as they are both downstream of the
phenotype and increase in importance with increased treatment
duration. Taken together, NOTCH was the only factor that appeared
in all inferred networks and was additionally shown to be involved
in early response to Olaparib in resistant cell lines.
Inhibition of NOTCH Signaling Sensitized Resistant Cells
to Olaparib
The combination of analysis techniques identified NOTCH as a
common target in BRCA1WT and BRCA1MT/RES cells to desensitize
them to Olaparib treatment. NOTCH protein overexpression in
BRCA1WT and BRCA1MT/RES cells was confirmed by Western blot
(Fig. 6A). Specifically, NOTCH3 was overexpressed while NOTCH1
expression was consistent between cell types. The direct role of
NOTCH signaling in PARP1 inhibitor-induced cell death and the
development of resistance was investigated by treating BRCA1WT
and BRCA1MT/RES cells with both Olaparib and g-secretase inhibitor
(GSI), which specifically inhibits NOTCH signaling (Fig. 6B). Cell
viability decreased for both resistant cell groups during
co-treatment, with BRCA1WT cells showing 40% decrease in
viability with co-treatment and BRCA1WT/RES cells showing 75%
decrease in viability by MTS assay. These results are consistent with
our identification of NOTCH activity as an important factor in
acquired Olaparib resistance, and they suggest that acquired
resistance independent of BRCA1 restoration is distinctly sensitive
to NOTCH inhibition in combination with Olaparib.
Discussion
Resistance to PARP inhibitors can proceed through a variety of
mechanisms. BRCA can be restored, thus preventing the
combination of events that lead to synthetic lethality (Barber
et al., 2013). Resistance can also proceed through enhanced drug
clearance (Lord and Ashworth, 2013; Rottenberg et al., 2008) or
secondary mutations that lead to deletion of the 53bp1 gene, which
prevents PARP action at the site of DNA damage (Jaspers et al.,
2013). Crucially important are the regulatory factors that can lead to
one or a combination of these events. This study identified core
transcription factors and pathways that distinguish parental
Figure 4. PLSDA analysis of transcription factor activity measurements from BRCA1MT (BRCA1 mutant, green), BRCA1WT (BRCA1 wild-type, red), and BRCA1MT/RES cells
(BRCA1 mutant with resistance to Olaparib, blue). Colored regions represent 95% confidence ellipses for each cell type. Specific TF activity patterns associated with each cell group
can be identified by the co-localization of the sample scores (A and C) and the TF loadings (B and D). (A and B) Single time point PLSDA using standardized activity measurements for
35 transcription factors at the was able to separate the three cell groups with 92.0% calibration accuracy and 91.7% cross-validation accuracy. (C and D) Combined time-course
PLSDA using standardized activity measurements for transcription factors at multiple time points after treatment with Olaparib. VIP scores were used to select 35 TF/time point
measurements that separate the three cell groupswith 99.7% calibration accuracy and 99.7% cross-validation accuracy. The labels on the loadings plot (D) indicate both the name of
the transcription factor being used and the elapsed time after the addition of Olaparib.
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HCC1937 cells (BRCAMT) from cells with restored BRCA1
(BRCA1WT) and cells with acquired resistance (BRCA1MT/RES),
using both supervised and unsupervised classification prior to
treatment with Olaparib. Because NOTCH was (i) significantly
different in the two resistant cell lines compared to the parental line;
(ii) in the top 10% of VIP scores via PLSDA on the dynamic TF
activity data; and (iii) implicated in the early response to Olaparib
by NTRACER, NOTCH inhibition was investigated in combination
with Olaparib treatment, and we observed that this combination
could overcome resistance.
The association of NOTCH with mutant BRCA1, sensitivity to
PARP inhibition, and upregulation following the development of
resistance is consistent with the role of NOTCH signaling in breast
cancer development. BRCA1 has been reported to upregulate
NOTCH signaling by transcriptionally upregulating NOTCH ligands
and receptors, which may be important for normal breast tissue
differentiation (Buckley et al., 2013). This role of NOTCH during
development would be consistent with the observation that BRCA1
mutation may prevent the ability to upregulate NOTCH. In human
breast cancer, aberrant activation of NOTCH1 has been observed
(Stylianou et al., 2006), and examination of breast cancer patients’
clinicopathological parameters reports that a high level of NOTCH1
may be associated with a poorer outlook for the breast cancer
patient, while a high level of NOTCH2 correlated to a higher chance
of survival (Parr et al., 2004). Herein, we report an association of
NOTCH signaling with PARP1 inhibitor-induced breast cancer cell
death, which was further validated by demonstration of increased
cell death following co-treatment with PARP1 and NOTCH signaling
inhibitors for BRCA1 wild-type and mutant cells. Furthermore,
PARP1 inhibitor-resistant BRCA1 mutant cells had an increased
expression of NOTCH3. NOTCH fusions have been reported in triple
negative breast cancer cells, which could provide a means for
upregulation of NOTCH activity despite BRCA1mutation (Robinson
et al., 2011), thereby providing resistance to PARP1i treatment. Our
results, combined with the increasing evidence supporting the
association of NOTCH pathways with breast cancer development,
suggest that PARP1 inhibitor-induced cell death and development of
resistance might be related to restored NOTCH activity, which is
lowered in the BRCA1-mutant cell type.
A key component to identifying NOTCH was the incorporation of
dynamic TF activity measurements, which improved the classifica-
tion accuracy of the models compared with static techniques. The
ability of the TRACER platform to capture dynamic changes
provides a distinct advantage over comparable techniques based on
Figure 5. Inferred regulatory networks in BRCA1MT/RES and BRCA1WT cells. Networks depict regulatory interactions relative to BRCAMT cells during the first 4 h of PARPi
treatment. White node indicates the cell type. Green edges indicate activating interaction, red edges indicate deactivating interactions. (A and B) networks for BRCA1RES/MT cells
from 0 to 2 and 2 to 4 h. (C and D) networks for BRCA1WT cells from 0 to 2 and 2 to 4 h.
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cell lysis and measurements of abundance, where acquiring
multiple time points can be prohibitively labor intensive or
expensive to perform. By measuring TF activity at multiple time
points in the live cell assays, the probable phenotype of the cell was
more easily classified, potentially recognizing resistance days before
the efficacy of treatment can be assessed. Incorporation of
dynamics into the supervised PLSDA model resulted in more than a
10-fold reduction in misclassified points compared to single time
point PLSDA. Importantly, 48 h of treatment andmeasurement were
used for classification in this study, which is before a significant
response was observed to the drug in sensitivity assays (Fig. 1).
Equally important, VIP scores identified NOTCH at 2 h as the top
scoring classifier in the model. Latent variable loadings in the
combined time-course PLSDAmodel indicate the association of this
early NOTCH response, but not the later response, with the resistant
phenotype, which supports the utility of comparing dynamic
measurements (Fig. 4). Static measurements would not have
identified the complex role of this factor, which ultimately proved
important to the development of resistance in the model system
(Fig. S3A).
Furthermore, the combination of analysis techniques used in this
study was essential to identifying NOTCH as a potential driver of
resistance to Olaparib. Statistical analysis is useful for finding
factors that are differentially regulated between cell types and
different time points of treatment, however, determining the factors
ultimately responsible for resistance is difficult to determine.
PLSDA was applied in this study to identify differences in the two
phenotypes (resistant and sensitive) as well as differences between
cells with different mechanisms of resistance. The latent variables
generated during PLSDA provide an excellent means for
representing multivariate TF activity measurements and a distinct
advantage over other classification techniques in visualization and
interpretation (Ballabio and Consonni, 2013). PLSDA allowed
identification of relationships between TFs (or “signatures”) that
best differentiated cell phenotypes. Additionally, PLSDA directly
complements these baseline statistical measurements by providing
ameasure of the factors that are “important”; that is, the factors that
can be used to identify one cell type from the others, and, through
the VIP score, rank, the relative importance of each factor within the
model. Network analysis (NTRACER) generated a model of the
factors that are directly connected to the phenotype, the factors that
are associated with the response to the drug, and how these factors
change in importance over time. The network analysis provided a
biological context for the PLSDAmeasurements, in which the role of
Figure 6. NOTCH signaling is related to PARPi resistance. (A) Notch3 protein was elevated in two PARPi resistant cell lines, while Notch1 protein was unchanged. (B)Three cell
lines (BRCAWT, BRCAMT, and BRCAMT/RES) were treated by 10mM of Olaparib, 0.5mM of GSI, and both for 7 days. The values were represented by the MTS ratio to DMSO-treated
control. Co-treatment of Olaparib and GSI significantly affected cell viability (P< 0.01).
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a particular factor in the response could be elucidated. In this study,
we tested one TF identified as a key hub by our network analysis, yet
future studies could use additional TF signatures to design
combinatorial therapies.
The techniques used in this study each suggested NOTCH
signaling as essential to the response of both resistant cell types,
though the analysis suggests BRCA1WT and BRCA1MT/RES have
distinct mechanisms of resistance. NOTCH activity is linked to the
BRCA1 protein and thus likely the cause of increased NOTCH
activity in the BRCA1WT cell line; this would also account for the
relative simplicity of the BRCA1WT network, as the response to
PARP inhibition would proceed through the BRCA1 protein, which
was not measured in these experiments. Conversely, NOTCH
signaling was associated with pluripotency markers (OCT4,
NANOG) in the BRCA1MT/RES cell lines by both PLSDA and
NTRACER. This association of NOTCH with OCT4 and NANOG is
consistent with previous reports in which signaling in resistant
cancer cells was connected with the cancer stem cell phenotype
(Bhola et al., 2016; D’Angelo et al., 2015; Qiu et al., 2013; Reya et al.,
2001; Ying et al., 2011). The association of pluripotency markers
(OCT4, NANOG) with BRCA1MT/RES cells but not BRCA1WT cells
possibly indicates a stem cell phenotype for these cells and that this
phenotype may enhance NOTCH activity that contributes to the
resistance to Olaparib.
In conclusion, we employed TRACER to report on the activity of
numerous TFs in BRCA1-mutated cells during treatment with
Olaparib and identified key TFs associated with PARP inhibition.
The NOTCH pathway was identified as a key factor in supporting
resistance to PARP inhibitor therapy through a combination of
techniques. The analysis strategies utilized here could be applied to
other cancer/therapy systems to identify pathways important to
drug resistance, as well as identify potential mechanisms for drug
action on these cells. Furthermore, strategies such as those
developed herein to identify NOTCH signaling may also be
employed to identify therapeutic targets critical to overcoming
resistance to a variety of pharmaceuticals, which is a mounting
challenge to the clinical management of advanced cancers.
This work was funded by NIH grant RO1GM097220-05 (J.S.J. and L.D.S.).
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